The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study

Elena I. Kovalenko; Коваленко Елена Игоревна; Elena V. Artamonova; Артамонова Елена Владимировна; Elena V. Karabina; Карабина Елена Владимировна; Irina I. Andreiashkina; Андреяшкина Ирина Ивановна; Ekaterina A. Prokof’eva; Прокофьева Екатерина Александровна; Nataliia O. Popova; Попова Наталия Олеговна; Elena A. Gaisina; Гайсина Елена Александровна; Irina V. Evstigneeva; Евстигнеева Ирина Владимировна; Mikhail V. Shaidorov; Шайдоров Михаил Владимирович; Larisa A. Zhiliaeva; Жиляева Лариса Анатольевна; Dmitrii M. Ponomarenko; Пономаренко Дмитрий Михайлович; Alfiia I. Khasanova; Хасанова Альфия Ирековна; Guzel Z. Mukhametshina; Мухаметшина Гузель Зиннуровна; Anton E. Koziakov; Козяков Антон Евгеньевич; Liudmila V. Vorotilina; Воротилина Людмила Викторовна; Anton Iu. Povyshev; Повышев Антон Юрьевич; Elena I. Simolina; Симолина Елена Ивановна; Vasilii V. Marfutov; Марфутов Василий Васильевич; Dmitrii V. Kozlov; Козлов Дмитрий Владимирович; Irina R. Suslova; Суслова Ирина Рудольфовна; Valentina E. Shikina; Шикина Валентина Евгеньевна; Tatiana V. Karandeeva; Карандеева Татьяна Вадимовна; Artem O. Shepel’; Шепель Артем Олегович; Liudmila V. Kramskaia; Крамская Людмила Викторовна; Denis A. Oskirko; Оскирко Денис Анатольевич; Olga S. Frolova; Фролова Ольга Сергеевна

doi:10.26442/18151434.2020.1.200058

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study

Authors: Kovalenko E.I.¹, Artamonova E.V.¹, Karabina E.V.², Andreiashkina I.I.³, Prokof’eva E.A.⁴, Popova N.O.⁵, Gaisina E.A.⁶, Evstigneeva I.V.⁷, Shaidorov M.V.⁸, Zhiliaeva L.A.⁹, Ponomarenko D.M.¹⁰, Khasanova A.I.¹¹, Mukhametshina G.Z.¹¹, Koziakov A.E.¹², Vorotilina L.V.¹³, Povyshev A.I.¹⁴, Simolina E.I.⁵, Marfutov V.V.³, Kozlov D.V.¹⁵, Suslova I.R.¹⁶, Shikina V.E.¹⁷, Karandeeva T.V.¹⁸, Shepel’ A.O.¹⁸, Kramskaia L.V.¹⁸, Oskirko D.A.¹⁸, Frolova O.S.¹⁹
Affiliations:
1. Blokhin National Medical Research Center of Oncology
2. Tula Regional Oncologic Dispensary
3. Loginov Moscow Clinical Scientific Practical Center
4. City Clinic №60
5. Tomsk National Research Medical Center
6. Multidisciplinary Clinical Medical Center “Medical City”
7. Tver Regional Clinical Oncology Center
8. Togliatti City Clinical Hospital №5
9. Kursk Regional Clinical Oncology Center
10. Regional Oncology Center
11. Republican Clinical Oncology Center
12. Novosibirsk Regional Clinical Oncology Center
13. Clinical Oncology Center
14. District Clinical Hospital
15. Diagnostic Clinical Center №1, branch №5
16. Oncology Center №4
17. Federal Research Center for Specialized Types of Medical Assistance and Medical Technologies
18. Pletnev City Clinical Hospital
19. Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncology)
Issue: Vol 22, No 1 (2020)
Pages: 53-59
Section: CLINICAL ONCOLOGY
URL: https://journals.rcsi.science/1815-1434/article/view/34173
DOI: https://doi.org/10.26442/18151434.2020.1.200058
ID: 34173

Cite item

Full Text

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

The article presents the experience of 19 Russian medical institutions on the use of eribulin in combination with trastuzumab in various treatment lines of metastatic HER2+ breast cancer in routine clinical practice.

Aim. The main objective of this retrospective observational study was to evaluate the efficacy and tolerability of eribulin and trastuzumab combo in HER2+ breast cancer patients pretreated with anthracyclines and taxanes. The analysis included 60 patients who received at least 2 cycles of eribulin in combination with trastuzumab. 2 patients (3.3%) received treatment as the 1st line, as the 2nd – 14 (23.3%), as the 3rd – 16 (26.7%), and as the 4th and more – 28 (46.7%).

Materials and methods. Complete response was achieved in 2 (3.3%) patients, partial response in 9 (15%), stable disease in 33 (55%), stabilization for more than 6 months in 11 (18.3%), disease progression was detected in 16 (26.7%) patients. The objective response rate was 18.3% in the whole group, the clinical benefit rate – 36.7%.

Results. The objective response rate in the group of the luminal subtype (ER/PR+HER2+) was 26.9%, in HER2-overexpressed subtype (ER-PR-HER2+) – 8.8% and 64.7%, respectively, disease progression was recorded 2.3 times more often – 35.3% versus 15.5% in the luminal subtype group. The median progression-free survival in patients with HER2+ breast cancer was 4.95 months (95% confidence interval – CI 3.04–8.29 months), in luminal subtype – 6.38 months (95% CI 3.33–8.54 months), in non-luminal – 4.44 months (95% CI 2.4–7.96 months); p=0.306. The treatment was well tolerated, the spectrum of adverse events corresponded to the eribulin toxicity profile.

Conclusions. The uniqueness of this study lies in the fact that on a large clinical material from the standpoint of real clinical practice, a very promising treatment regimen that is not used routinely in a number of countries has been studied, its effectiveness and satisfactory tolerance have been confirmed.

Keywords

breast cancer, eribulin, efficacy, tolerance

Full Text

##article.viewOnOriginalSite##

About the authors

Elena I. Kovalenko

Blokhin National Medical Research Center of Oncology

Author for correspondence.
Email: eikovalenko@mail.ru
ORCID iD: 0000-0003-4763-7992

Cand. Sci. (Med.)

Russian Federation, Moscow

Elena V. Artamonova

Blokhin National Medical Research Center of Oncology

Email: eikovalenko@mail.ru

D. Sci. (Med.)

Russian Federation, Moscow

Elena V. Karabina

Tula Regional Oncologic Dispensary

Email: eikovalenko@mail.ru
ORCID iD: 0000-0002-8936-3590

Branch manager

Russian Federation, Tula

References

Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–82.
Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 334: 783–92.
Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592–600.
Cortazar P, Johnson JR, Justice R, Pazdur R. Metastatic breast cancer (MBC): FDA approval overview. Proc. ASCO 2008. J Clin Oncol 2008; 26: 15S (аbstr. 1013).
Peacock NW, Infante JR, Yardley DA et al. Phase II trial of weekly docetaxel, vinorelbine and trastuzumab in the first-line treatment of patients (pts) with HER-2-positive metastatic breast cancer (MBC). Proc. ASCO 2008. J Clin Oncol 2008; 26: 49S (abstr. 1032).
Kash J, Barlow WE, Albain KS et al. Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER-2-positive stage IV breast cancer. Proc. ASCO 2008. J Clin Oncol 2008; 26: 49S (abstr. 1033).
Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733–43.
Swain SM, Baselga J, Kim SB et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724–34.
Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280–90.
Barok M, Tanner M, Koninki K et al. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 2011; 13: R46.
Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783–91.
Krop IE, Kim SB, Martin AG et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol 2017; 18: 743–54.
Giordano SH, Temin S, Chandarlapaty S et al. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018; 36 (26): 2736–40.
Kaufman PA, Cortes J, Awada A et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes: subgroup analyses. J Clin Oncol 2013; 31 (Suppl.; abstr. 1049).
Twelves C, Cortes J, Vandat L et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 2014; 148: 553–61.
Pivot Х, Marmé F, Koenigsberg R et al. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 2016; 27 (8): 1525–31.
Wilks S, Puhalla S, O’Shaughnessy S et al. Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer. Clin Breast Cancer 2014; 14 (6): 405–12.
Халавен. Инструкция по применению лекарственного препарата для медицинского применения, утвержденная Минздравом России 15.06.2016. [Khalaven. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia, utverzhdennaia Minzdravom Rossii 15.06.2016 (in Russian).]
Krop IE, Kim SB, González-Martín A et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 689–99.
Lutrino SE, Orlando L, Fontanella C et al. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients: Results on safety and efficacy – An Italian multicenter experience. J Clin Oncol 2016; 34 (Suppl. 15): e12087.
Mougalian SS, Copher R, McAllister L et al. Outcomes of real-world use of eribulin plus trastuzumab for HER2-positive metastatic breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4–8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019; 79 (Suppl. 4): Abstr. nr P6-17-28.

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

2. Fig. 1. Localization of metastases (n=60).

Download (125KB)

Indexing metadata

3. Fig. 2. Chemotherapy lines of eribulin in patients with HER2-positive metastatic breast cancer (n=60).

Download (193KB)

Indexing metadata

4. Fig. 3. Progression-free survival (PFS) in HER2-positive metastatic breast cancer (n=60).

Download (196KB)

Indexing metadata

5. Fig. 4. PFS in luminal and non-luminal HER2-positive metastatic breast cancer.

Download (199KB)

Indexing metadata

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study

Full Text

Abstract

Keywords

Full Text

About the authors

References

Supplementary files

This website uses cookies